Rafael Ferreira Dantas

Dr. Rafael Ferreira Dantas


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2019 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
CPCarolina Escardó Pereyra
Carolina Escardó Pereyra
RDRafael Ferreira Dantas
Rafael Ferreira Dantas
SFSabrina Baptista Baptista Ferreira
Sabrina Baptista Baptista Ferreira
LGLuciano Pinho Gomes
Luciano Pinho Gomes
FSFloriano Silva-Jr
Floriano Silva-Jr
Cancer is one of the leading causes of death around the world and although the different clinical approaches have helped to increase survival rates, incidence is still high and so its mortality. Chemotherapy is the only approach which is systemic, reaching cancer cells in all body tissues and the search for new potent and selective drugs is still an attractive field within cancer research. Naphthoquinones, natural and synthetic, have garnered much attention in the scientific community due to their pharmacological properties, among them anticancer action, and potential therapeutic significance. Many mechanisms of action have been reported which also depend on structural differences among them. Here, we describe some of the most relevant mechanisms of action reported so far for naphthoquinones and highlight novel targets which are being described in the literature. Furthermore, we gather some of the most impressive efforts done by researchers to harness the anticancer properties of these compounds through specifically designed structural modifications.

24 January 2022 in Molecules
Verified
Journal Article
Open access
PDF file
AOAndressa Oliveira
Andressa Oliveira
SMStefany Moura
Stefany Moura
LPLuiz Claudio Ferreira Pimentel
Luiz Claudio Ferreira Pimentel
JNJoão Neto
João Neto
RDRafael Ferreira Dantas
Rafael Ferreira Dantas
NBNubia Boechat
Nubia Boechat
Tyrosine kinase enzymes are among the primary molecular targets for the treatment of some human neoplasms, such as those in lung cancer and chronic myeloid leukemia. Mutations in the enzyme domain can cause resistance and new inhibitors capable of circumventing these mutations are highly desired. The objective of this work was to synthesize and evaluate the antiproliferative ability of ten new analogs that contain isatins and the phenylamino-pyrimidine pyridine (PAPP) skeleton, the main pharmacophore group of imatinib. The 1,2,3-triazole core was used as a spacer in the derivatives through a click chemistry reaction and gave good yields. All the analogs were tested against A549 and K562 cells, lung cancer and chronic myeloid leukemia (CML) cell lines, respectively. In A549 cells, the 3,3-difluorinated compound (3a), the 5-chloro-3,3-difluorinated compound (3c) and the 5-bromo-3,3-difluorinated compound (3d) showed IC50 values of 7.2, 6.4, and 7.3 μM, respectively, and were all more potent than imatinib (IC50 of 65.4 μM). In K562 cells, the 3,3-difluoro-5-methylated compound (3b) decreased cell viability to 57.5% and, at 10 µM, showed an IC50 value of 35.8 μM (imatinib, IC50 = 0.08 μM). The results suggest that 3a, 3c, and 3d can be used as prototypes for the development of more potent and selective derivatives against lung cancer.

18 July 2019 in Medicinal Chemistry Research
Verified
Journal Article
Closed access
PDF file
RDRafael Ferreira Dantas
Rafael Ferreira Dantas
MSMario R. Senger
Mario R. Senger
MCMariana F. C. Cardoso
Mariana F. C. Cardoso
Vitor ferreiraVitor ferreira
Vitor ferreira
MSMaria Cecília B.V. De Souza
Maria Cecília B.V. De Souza
FSFloriano Silva-Jr
Floriano Silva-Jr